<DOC>
	<DOC>NCT00774332</DOC>
	<brief_summary>A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL</brief_summary>
	<brief_title>A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL</brief_title>
	<detailed_description>The feasibility will be evaluated in terms of complete remission rate, duration of complete remission, disease-free survival, overall survival, and toxicities.</detailed_description>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<criteria>Patients with relapsed/resistant acute lymphoblastic leukemia Patients must be between 15 and 65 years of age. Estimated life expectancy of more than 3 months ECOG performance status of 2 or lower, Karnofsky scale &gt; 60 (see appendix I) Adequate cardiac function (EF&gt;45%) on echocardiogram or MUGA scan Adequate kidney function (estimated Ccr &gt;50 ml/min) Patients with CNS involvement of leukemic blasts will not be excluded. Patients with extramedullary relapse(s) only will be excluded.</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>